Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Multicenter, 2-Part, Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Study to Assess the Safety, Tolerability, PK and PD of MK0941 on Postprandial Plasma Glucose Concentrations After Daily Administration MK0941 Before Each Meal in Subjects With T2D Being Treated With Basal Insulin.

Next Previous
Trial Profile

Multicenter, 2-Part, Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Study to Assess the Safety, Tolerability, PK and PD of MK0941 on Postprandial Plasma Glucose Concentrations After Daily Administration MK0941 Before Each Meal in Subjects With T2D Being Treated With Basal Insulin.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 09 May 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs MK 0941 (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions
  • Sponsors Merck Sharp & Dohme

Most Recent Events

  • 28 Jun 2011 Acutal patient number (70) reported at the 71st Annual Scientific Sessions of the American Diabetes Association.
  • 28 Jun 2011 Results presented at the 71st Annual Scientific Sessions of the American Diabetes Association.
  • 07 Apr 2009 Actual patient number (66) added as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top